Search

Your search keyword '"Gasparro D"' showing total 4 results
Start Over Author "Gasparro D" Topic adenocarcinoma
4 results on '"Gasparro D"'

1. Testicular metastasis of prostate adenocarcinoma: the other side of orchiepididymitis.

Author

Di Rienzo G, Tafuni A, Maestroni U, Ruffini L, Silini EM, Gasparro D, Pilato FP, and Gnetti L

Subjects
Male, Humans, Aged, Prostate pathology, Pain etiology, Adenocarcinoma complications, Adenocarcinoma diagnosis, Adenocarcinoma pathology, Prostatic Neoplasms diagnosis, Testicular Neoplasms diagnosis, Testicular Neoplasms surgery, Carcinoma
Abstract

Background: Metastatic prostate adenocarcinoma is a rare event and there are few references to this topic. We report an unusual case of prostate cancer metastasis and review of contemporary literature. Moreover, we discuss the pathogenesis and the clinical aspects of this event., Case Presentation: A 70-year-old patient was admitted to the hospital for right scrotal pain. The ultrasound examination described an increase in testicular size, suggesting the possibility of orchiepididymitis. Past medical history reported a previous prostate adenocarcinoma. Inflammatory blood tests were normal. Importantly, PSA was 3.3 ng/ml. PET scan positivity in the scrotum raised suspicion of a relapse. Therefore, he underwent right orchiectomy., Conclusion: Although metastatic prostate adenocarcinoma is rare, a correct diagnosis is of paramount importance because the therapy changes accordingly. Patients who complain of scrotal pain need to be examined accurately. Although the most common cause behind this symptom is infectious, the patient's past medical history should be reviewed to exclude previous malignancies., (Copyright © 2024 Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology.)

Published
2024
Full Text
View/download PDF

2. ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients.

Author

Bozzetti C, Nizzoli R, Tiseo M, Squadrilli A, Lagrasta C, Buti S, Gasparro D, Zanoni D, Majori M, De Filippo M, Mazzoni F, Maddau C, Naldi N, Sammarelli G, Frati C, Pinto C, and Ardizzoni A

Subjects
Adenocarcinoma diagnosis, Adenocarcinoma of Lung, Adult, Aged, Aged, 80 and over, Anaplastic Lymphoma Kinase, Carcinoma, Non-Small-Cell Lung surgery, Cytodiagnosis methods, Female, Gene Rearrangement physiology, Humans, In Situ Hybridization, Fluorescence methods, Lung Neoplasms diagnosis, Lung Neoplasms pathology, Lung Neoplasms surgery, Male, Middle Aged, Adenocarcinoma pathology, Carcinoma, Non-Small-Cell Lung metabolism, Lung Neoplasms metabolism, Protein-Tyrosine Kinases metabolism, Proto-Oncogene Proteins metabolism, Receptor Protein-Tyrosine Kinases metabolism
Abstract

Background: The identification of ALK and ROS1 rearrangements and the availability of an effective target therapy, such as crizotinib, represent a new option in the treatment of advanced non-small cell lung cancer (NSCLC) patients. In light of recent advances in non-invasive diagnostic procedures, we aimed to demonstrate that direct cytological smears are suitable for assessing ALK and ROS1 rearrangements in patients with NSCLC., Methods: Fifty-five patients with a cytological diagnosis of lung adenocarcinoma (ADC) were evaluated for ALK rearrangements by fluorescence in situ hybridization (FISH) and 12 patients for ROS1 FISH rearrangements. Seventeen of the 55 cytological samples tested for ALK were obtained from the primary tumor and 38 from metastatic lesions. Ten of 12 samples evaluated for ROS1 were obtained from metastatic sites and two from the primary tumor., Results: ALK FISH was successful in 49/55 (89%) cytological ADC samples and ROS1 FISH in all 12 cytological samples. ALK rearrangements were found in 3/13 (23%) primary tumors and 7/36 (19%) metastatic sites. ROS1 rearrangements were found in one of the two primary tumors and in two of the 10 metastases. Two of the three rearranged cases were tested on cytology after knowing that they were rearranged on histology in order to increase representativeness of ROS1 rearranged cases in this study., Conclusion: Whenever cytology represents the only available material for diagnosis and biological characterization of NSCLC, minimally invasive procedures may provide an additional important source of cellular material for FISH assessment of ALK and ROS1 rearrangements., (© 2015 Wiley Periodicals, Inc.)

Published
2015
Full Text
View/download PDF

3. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.

Author

Bozzetti C, Negri FV, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, Gardini G, Nizzoli R, Leonardi F, Gasparro D, Camisa R, Cavalli S, Silini EM, and Ardizzoni A

Subjects
Adenocarcinoma drug therapy, Aged, Aged, 80 and over, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Agents therapeutic use, Ascitic Fluid chemistry, Clinical Trials as Topic, Esophagogastric Junction, Female, Gene Expression Regulation, Neoplastic, Humans, Liver Neoplasms chemistry, Liver Neoplasms secondary, Lymphatic Metastasis, Male, Middle Aged, Peritoneal Neoplasms chemistry, Peritoneal Neoplasms secondary, Pleural Effusion, Malignant chemistry, Skin Neoplasms chemistry, Skin Neoplasms secondary, Stomach Neoplasms drug therapy, Trastuzumab, Up-Regulation, Adenocarcinoma chemistry, Adenocarcinoma pathology, Biomarkers, Tumor analysis, Immunohistochemistry, In Situ Hybridization, Fluorescence, Receptor, ErbB-2 analysis, Stomach Neoplasms chemistry, Stomach Neoplasms pathology
Abstract

Background: Trastuzumab has recently shown efficacy in the treatment of HER2-positive advanced gastric adenocarcinoma. Although antibody-based therapies target the metastatic disease, HER2 status is usually evaluated in the primary tumour because metastatic sites are rarely biopsied. The aim of this study was to compare HER2 status in primary and paired metastatic sites of gastric adenocarcinoma., Methods: The HER2 status was assessed by fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC) in 72 secondary lesions of gastric adenocarcinoma and in the corresponding primary tumours., Results: Concordance of FISH results, evaluable in 68 primary and matched metastatic sites, was 98.5%. Concordance of IHC results, available in 39 of the 72 paired cases, was 94.9%. Only one case showed discordance between primary tumour and metastasis, being negative by both IHC and FISH in the primary and showing HER2 overexpression and amplification in the corresponding pancreatic lymph node metastasis., Conclusion: The high concordance observed between HER2 results obtained by both IHC and FISH on primary tumours and corresponding metastases suggests that in gastric cancer HER2 status is maintained in most cases unchanged during the metastatic process.

Published
2011
Full Text
View/download PDF

4. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma

Author

C, Bozzetti, F V, Negri, C A, Lagrasta, P, Crafa, C, Bassano, I, Tamagnini, G, Gardini, R, Nizzoli, F, Leonardi, D, Gasparro, R, Camisa, S, Cavalli, S, Capelli, E M, Silini, A, Ardizzoni, Bozzetti C, Negri FV, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, Gardini G, Nizzoli R, Leonardi F, Gasparro D, Camisa R, Capelli S, Silini EM, and Ardizzoni A

Subjects
Male, Oncology, Pathology, Cancer Research, Skin Neoplasms, Receptor, ErbB-2, Gastric carcinoma, Gastroenterology, Metastasis, Trastuzumab, Ascitic Fluid, Medicine, Stomach cancer, skin and connective tissue diseases, In Situ Hybridization, Fluorescence, Peritoneal Neoplasms, Aged, 80 and over, Clinical Trials as Topic, Liver Neoplasms, Antibodies, Monoclonal, Middle Aged, Immunohistochemistry, Up-Regulation, Gene Expression Regulation, Neoplastic, Lymphatic Metastasis, Adenocarcinoma, Female, Esophagogastric Junction, Corrigendum, HER2, gastric cancer, FISH, immunohistochemistry, medicine.drug, medicine.medical_specialty, Concordance, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Pancreatic Lymph Node, FISH, Stomach Neoplasms, HER2, Internal medicine, Biomarkers, Tumor, Humans, Aged, business.industry, gastric cancer, Cancer, medicine.disease, Pleural Effusion, Malignant, Clinical Study, business
Abstract

Background: Trastuzumab has recently shown efficacy in the treatment of HER2-positive advanced gastric adenocarcinoma. Although antibody-based therapies target the metastatic disease, HER2 status is usually evaluated in the primary tumour because metastatic sites are rarely biopsied. The aim of this study was to compare HER2 status in primary and paired metastatic sites of gastric adenocarcinoma. Methods: The HER2 status was assessed by fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC) in 72 secondary lesions of gastric adenocarcinoma and in the corresponding primary tumours. Results: Concordance of FISH results, evaluable in 68 primary and matched metastatic sites, was 98.5%. Concordance of IHC results, available in 39 of the 72 paired cases, was 94.9%. Only one case showed discordance between primary tumour and metastasis, being negative by both IHC and FISH in the primary and showing HER2 overexpression and amplification in the corresponding pancreatic lymph node metastasis. Conclusion: The high concordance observed between HER2 results obtained by both IHC and FISH on primary tumours and corresponding metastases suggests that in gastric cancer HER2 status is maintained in most cases unchanged during the metastatic process. Keywords: HER2, gastric cancer, FISH, immunohistochemistry

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results